ATE362929T1 - Pyridinderivate als inhibitoren der raf-kinase - Google Patents

Pyridinderivate als inhibitoren der raf-kinase

Info

Publication number
ATE362929T1
ATE362929T1 AT02779311T AT02779311T ATE362929T1 AT E362929 T1 ATE362929 T1 AT E362929T1 AT 02779311 T AT02779311 T AT 02779311T AT 02779311 T AT02779311 T AT 02779311T AT E362929 T1 ATE362929 T1 AT E362929T1
Authority
AT
Austria
Prior art keywords
kinase inhibitors
raf kinase
pyridine derivatives
raf
migraine
Prior art date
Application number
AT02779311T
Other languages
English (en)
Inventor
Mark Bamford
David Dean
Antoinette Naylor
Andrew Takle
David Wilson
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of ATE362929T1 publication Critical patent/ATE362929T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Insulating Materials (AREA)
AT02779311T 2001-09-05 2002-09-05 Pyridinderivate als inhibitoren der raf-kinase ATE362929T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0121490.7A GB0121490D0 (en) 2001-09-05 2001-09-05 Ciompounds

Publications (1)

Publication Number Publication Date
ATE362929T1 true ATE362929T1 (de) 2007-06-15

Family

ID=9921558

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02779311T ATE362929T1 (de) 2001-09-05 2002-09-05 Pyridinderivate als inhibitoren der raf-kinase

Country Status (11)

Country Link
US (1) US7452906B2 (de)
EP (1) EP1423384B1 (de)
JP (1) JP2005504794A (de)
AT (1) ATE362929T1 (de)
CY (1) CY1106766T1 (de)
DE (1) DE60220290T2 (de)
DK (1) DK1423384T3 (de)
ES (1) ES2284939T3 (de)
GB (1) GB0121490D0 (de)
PT (1) PT1423384E (de)
WO (1) WO2003022840A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189745B1 (en) 1999-11-22 2007-03-13 Smithkline Beecham Corporation Compounds
DE60103136T2 (de) * 2000-03-06 2004-10-28 Smithkline Beecham Plc, Brentford Imidazolderivate als Raf-Kinase Inhibitoren
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
EP1432703A1 (de) * 2001-09-05 2004-06-30 Smithkline Beecham Plc Heterocycle-carboxamide derivate als raf kinase inhibitoren
NZ535591A (en) 2002-02-28 2006-07-28 Astrazeneca Ab Oxazolidinone derivatives, processes for their preparation, and pharmaceutical compositions containing them
AU2003207340A1 (en) 2002-02-28 2003-09-09 Astrazeneca Ab 3-cyclyl-5-(nitrogen-containing 5-membered ring) methyl-oxazolidinone derivatives and their use as antibacterial agents
WO2003086467A1 (en) * 2002-04-08 2003-10-23 Smithkline Beecham Corporation Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
US20090264494A1 (en) * 2002-10-18 2009-10-22 Board Of Regents, The University Of Texas System Use of neuroprotective 3-substituted indolone compositions
US20050250837A1 (en) * 2002-10-18 2005-11-10 D Mello Santosh R Use of C-Raf inhibitors for the treatment of neurodegenerative diseases
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
EP1951728A4 (de) * 2005-11-04 2011-04-20 Glaxosmithkline Llc Thienopyridine als inhibitoren von b-raf-kinase
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP2265610B1 (de) 2008-02-29 2012-12-12 Array Biopharma, Inc. Pyrazol[3,4-b]pyridin-raf-inhibitoren
EP2265574A1 (de) 2008-02-29 2010-12-29 Array Biopharma, Inc. N-(6-aminopyridin-3-yl)-3-(sulfonamido)benzamidderivate als b-raf-inhibitoren zur behandlung von krebs
JP2013503189A (ja) 2009-08-28 2013-01-31 アレイ バイオファーマ、インコーポレイテッド Ｒａｆ阻害化合物およびその使用方法
SG178899A1 (en) 2009-08-28 2012-04-27 Array Biopharma Inc Raf inhibitor compounds and methods of use thereof
CN102666498A (zh) 2009-08-28 2012-09-12 健泰科生物技术公司 Raf抑制剂化合物及其使用方法
CA2772316A1 (en) 2009-08-28 2011-03-03 Array Biopharma Inc. 1h-pyrazolo [3,4-b] pyridine compounds for inhibiting raf kinase
JP2013503190A (ja) 2009-08-28 2013-01-31 アレイ バイオファーマ、インコーポレイテッド Ｒａｆ阻害化合物およびその使用方法
EP2470538A1 (de) 2009-08-28 2012-07-04 Array Biopharma, Inc. Raf-hemmende verbindungen und anwendungsverfahren dafür
AU2010341229A1 (en) * 2009-12-17 2012-08-02 Merck Patent Gmbh Sphingosine kinase inhibitors
WO2012118492A1 (en) 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
EP3046557A1 (de) 2013-09-20 2016-07-27 Stichting Het Nederlands Kanker Instituut Rock in kombination mit mapk-signalweg
AU2014368906B2 (en) * 2013-12-20 2020-04-30 Biomed Valley Discoveries, Inc. Cancer treatment using combinations of ERK and RAF inhibitors
WO2018125983A1 (en) 2016-12-30 2018-07-05 Mitobridge, Inc. Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7629594A (en) 1993-07-21 1995-02-20 Smithkline Beecham Corporation Imidazoles for treating cytokine mediated disease
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
WO2002024680A1 (en) * 2000-09-21 2002-03-28 Smithkline Beecham P.L.C. Imidazole derivatives as raf kinase inhibitors

Also Published As

Publication number Publication date
US20040235843A1 (en) 2004-11-25
GB0121490D0 (en) 2001-10-24
US7452906B2 (en) 2008-11-18
DE60220290D1 (de) 2007-07-05
PT1423384E (pt) 2007-08-24
ES2284939T3 (es) 2007-11-16
DE60220290T2 (de) 2008-01-31
JP2005504794A (ja) 2005-02-17
CY1106766T1 (el) 2012-05-23
WO2003022840A1 (en) 2003-03-20
DK1423384T3 (da) 2007-09-24
EP1423384A1 (de) 2004-06-02
EP1423384B1 (de) 2007-05-23

Similar Documents

Publication Publication Date Title
DE60220290D1 (de) Pyridinderivate als inhibitoren der raf-kinase
DE60112312D1 (de) Imidazolderivate als raf-kinase-inhibitoren
DE60315146D1 (de) Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
ATE435015T1 (de) Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
DE60319158D1 (de) Pyrazoloisoquinolinenderivaten als kinase inhibitoren
GB0402137D0 (en) Novel compounds
BRPI0411365A (pt) derivados de aminopiridina
DE50310516D1 (de) Fredericamycin-derivate
GB0402143D0 (en) Novel compounds
CY1111083T1 (el) Παραγωγα νικοτιναμιδιου χρησιμα ως αναστολεις της p38
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
DE60318177D1 (de) Rho-kinase inhibitoren
DE60228098D1 (de) Pyridin-substituierte furanderivate als raf-kinase inhibitoren
DK1325011T3 (da) Fremgangsmåder og forbindelser til behandling af proliferative sygdomme
GB0402138D0 (en) Novel compounds
DE60328603D1 (de) Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
ATE336489T1 (de) Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren
NO20055307D0 (no) Substituerte isokromanforbindelser for behandling av metabolske forstyrrelser, kreft og andre sykdommer
ATE476419T1 (de) Isochinolinon-kaliumkanalinhibitoren
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
UA96570C2 (ru) Лиганды н3-рецептора гистамина и их терапевтические применения
EA200700098A1 (ru) Производные 4-арилморфолин-3-она, их получение и их применение в терапии
TW200602023A (en) Monocyclic heterocycles as kinase inhibitors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1423384

Country of ref document: EP

REN Ceased due to non-payment of the annual fee